In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist
- PMID:17001660
- DOI: 10.1002/syn.20330
In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist
Abstract
Present Parkinson's disease treatment strategies are far from ideal for a variety of reasons; it has therefore been suggested that partial dopamine receptor agonism might be a potential therapeutic approach with potentially fewer side effects. In the present study, we describe the in vitro characterization of the nonergot ligand SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolonemonohydrochloride). SLV308 binds to dopamine D(2), D(3), and D(4) receptors and 5-HT(1) (A) receptors and is a partial agonist at dopamine D(2) and D(3) receptors and a full agonist at serotonin 5-HT(1) (A) receptors. At cloned human dopamine D(2,L) receptors, SLV308 acted as a potent but partial D(2) receptor agonist (pEC(50) = 8.0 and pA(2) = 8.4) with an efficacy of 50% on forskolin stimulated cAMP accumulation. At human recombinant dopamine D(3) receptors, SLV308 acted as a partial agonist in the induction of [(35)S]GTPgammaS binding (intrinsic activity of 67%; pEC(50) = 9.2) and antagonized the dopamine induction of [(35)S]GTPgammaS binding (pA(2) = 9.0). SLV308 acted as a full 5-HT(1) (A) receptor agonist on forskolin induced cAMP accumulation at cloned human 5-HT(1) (A) receptors but with low potency (pEC(50) = 6.3). In rat striatal slices SLV308 concentration-dependently attenuated forskolin stimulated accumulation of cAMP, as expected for a dopamine D(2) and D(3) receptor agonist. SLV308 antagonized the inhibitory effect of quinpirole on K(+)-stimulated [(3)H]-dopamine release from rat striatal slices (pA(2) = 8.5). In the same paradigm, SLV308 had antagonist properties in the presence of quinpirole (pA(2) = 8.5), but the partial D(2) agonist terguride had much stronger antagonistic properties. In conclusion, SLV308 combines high potency partial agonism at dopamine D(2) and D(3) receptors with full efficacy low potency serotonin 5-HT(1) (A) receptor agonism and is worthy of profiling in in vivo models of Parkinson's disease.
Similar articles
- An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.Jones CA, Johnston LC, Jackson MJ, Smith LA, van Scharrenburg G, Rose S, Jenner PG, McCreary AC.Jones CA, et al.Eur Neuropsychopharmacol. 2010 Aug;20(8):582-93. doi: 10.1016/j.euroneuro.2010.03.001.Eur Neuropsychopharmacol. 2010.PMID:20434890
- Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH.Heinrich JN, et al.Eur J Pharmacol. 2006 Dec 15;552(1-3):36-45. doi: 10.1016/j.ejphar.2006.08.063. Epub 2006 Sep 14.Eur J Pharmacol. 2006.PMID:17056032
- S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, Peglion JL.Millan MJ, et al.J Pharmacol Exp Ther. 2004 Jun;309(3):903-20. doi: 10.1124/jpet.103.062398. Epub 2004 Feb 20.J Pharmacol Exp Ther. 2004.PMID:14978194
- [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].Tadori Y, Kikuchi T.Tadori Y, et al.Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18.Nihon Shinkei Seishin Yakurigaku Zasshi. 2012.PMID:22568121Review.Japanese.
- Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance.Maggio R, Millan MJ.Maggio R, et al.Curr Opin Pharmacol. 2010 Feb;10(1):100-7. doi: 10.1016/j.coph.2009.10.001. Epub 2009 Nov 5.Curr Opin Pharmacol. 2010.PMID:19896900Review.
Cited by
- The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P.Jackson MJ, et al.J Neural Transm (Vienna). 2010 Jan;117(1):55-67. doi: 10.1007/s00702-009-0323-9. Epub 2009 Oct 7.J Neural Transm (Vienna). 2010.PMID:19809864
- Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?Mailman RB, Murthy V.Mailman RB, et al.Curr Pharm Des. 2010;16(5):488-501. doi: 10.2174/138161210790361461.Curr Pharm Des. 2010.PMID:19909227Free PMC article.Review.
- Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W.Del Bello F, et al.Biomolecules. 2019 Apr 9;9(4):142. doi: 10.3390/biom9040142.Biomolecules. 2019.PMID:30970612Free PMC article.Review.
- Classification of 5-HT(1A) receptor agonists and antagonists using GA-SVM method.Zhu XL, Cai HY, Xu ZJ, Wang Y, Wang HY, Zhang A, Zhu WL.Zhu XL, et al.Acta Pharmacol Sin. 2011 Nov;32(11):1424-30. doi: 10.1038/aps.2011.112. Epub 2011 Oct 3.Acta Pharmacol Sin. 2011.PMID:21963891Free PMC article.
- International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D.Barnes NM, et al.Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552.Pharmacol Rev. 2021.PMID:33370241Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical